Guideline Recommendations for Fosfomycin Use in Uncomplicated Urinary Tract Infection

Guideline Positions

The 2024 WHO Essential Medicines guidelines exclude fosfomycin from first‑line recommendations for lower urinary tract infection, citing inferior efficacy compared with nitrofurantoin in randomized trials and higher drug cost. 1
The 2024 European Association of Urology (EAU) guidelines list a single 3‑g oral dose of fosfomycin tromethamine as a first‑line option for uncomplicated cystitis in women. 2
The 2011 IDSA/ESMID guidelines recognize that fosfomycin has lower early bacterial eradication than other first‑line agents but endorse its use because of single‑dose convenience, low resistance rates (< 1 % of E. coli isolates), minimal disruption of gut microbiota, and activity against multidrug‑resistant pathogens such as ESBL‑producing Enterobacterales and vancomycin‑resistant enterococci. [3][4]

Women with uncomplicated cystitis who prefer a single‑dose regimen may be treated with fosfomycin 3 g orally, especially when local resistance to trimethoprim‑sulfamethoxazole exceeds 20 %. 2
Infections caused by multidrug‑resistant Enterobacterales (including ESBL‑producers) or vancomycin‑resistant enterococci are appropriate indications for fosfomycin, as oral alternatives are limited. 3
Settings with high local resistance to trimethoprim‑sulfamethoxazole or fluoroquinolones support the use of fosfomycin to preserve the efficacy of those agents. 3

Do not use fosfomycin for pyelonephritis or upper urinary tract infections; efficacy data are lacking and the drug is not recommended for severe or systemic infections. 1
Avoid empiric use in men because most efficacy data derive from female cohorts; men generally require a 7‑day regimen with other agents. (Not cited)
Avoid fosfomycin in first‑trimester pregnancy due to insufficient safety data, despite FDA pregnancy category B. (Not cited)
Severe renal impairment (creatinine clearance < 54 mL/min) prolongs elimination half‑life and reduces urinary excretion, making fosfomycin less reliable; alternative agents should be considered. (Not cited)
Routine susceptibility testing for fosfomycin is often unavailable, so clinicians should rely on local resistance patterns when selecting therapy. 3

A single 3‑gram oral dose of fosfomycin tromethamine is the appropriate regimen for adults with acute uncomplicated cystitis. 5, 6, 7

In adult patients treated with the single 3‑g dose, early clinical cure rates range from 83 % to 91 % at the first follow‑up visit. (Evidence from prospective clinical studies.) 8, 9
Microbiological eradication at the first follow‑up is 78 %–80 %, which is significantly lower than that achieved with nitrofurantoin (86 %; p = 0.02). (Randomized comparative trial.) 10, 11
Late clinical response (4–6 weeks post‑treatment) remains high, with cure rates of 93 %–94 %. (Extended‑follow‑up data from the same trial cohort.) 10, 11

The IDSA/ESBL guideline panel notes that fosfomycin “appears to have inferior efficacy compared with standard short‑course regimens” based on FDA‑submitted data, but its use is justified by low resistance and minimal collateral damage. (Guideline commentary.) 5, 6, 7
Resistance among Escherichia coli isolates remains < 1 % and has been stable over the past five decades, supporting its continued first‑line role. (Surveillance data.) 8
Fosfomycin’s antimicrobial spectrum includes activity against vancomycin‑resistant Enterococci (VRE) and extended‑spectrum β‑lactamase (ESBL)‑producing organisms. (Microbiological profiling.) 8
Compared with fluoroquinolones or other broad‑spectrum agents, fosfomycin generates minimal ecological impact, reflecting low disruption of the gut microbiota. (Observational ecological studies.) 5, 6, 7

For uncomplicated cystitis caused by MDR Enterobacterales or VRE, the same single 3‑g oral dose is recommended as an effective regimen. (Evidence from recent MDR‑focused clinical investigations.) 12, 13, 14

Pyelonephritis: Oral fosfomycin should not be used for upper‑tract infections because data supporting efficacy are lacking. (Safety and efficacy review.) 9
Male patients: Empiric use in men is not advised; most efficacy data derive from female cohorts. (Gender‑specific evidence gap.) 9

The European Association of Urology (EAU) 2024 lists a single 3‑g oral dose of fosfomycin tromethamine as a first‑line therapy for uncomplicated cystitis in adult women, acknowledging a slightly lower early bacterial eradication rate (78–80 %) versus nitrofurantoin (86 %) but emphasizing its convenience and low resistance profile. 18
The IDSA/ESMID guidelines also recognize fosfomycin as a first‑line option for uncomplicated lower UTI, aligning with the EAU recommendation. 18

For asymptomatic bacteriuria in the second and third trimesters, the EAU 2024 endorses a single 3‑g oral dose of fosfomycin. 18

Guideline Body	Position on Fosfomycin for Lower UTI	Rationale / Key Points
EAU 2024	First‑line recommendation	Single‑dose convenience, resistance < 1 %, minimal impact on gut microbiota, activity against MDR pathogens; acknowledges lower early eradication.
IDSA/ESMID 2011	First‑line recommendation	Same advantages as EAU; supports use when trimethoprim‑sulfamethoxazole resistance > 20 % or MDR organisms suspected.
WHO 2024	Excludes fosfomycin from first‑line list	Cites inferior efficacy compared with nitrofurantoin and higher cost.

The EAU and IDSA/ESMID positions are supported by clinical data, whereas the WHO recommendation reflects a more conservative stance. 18

The Journal of Microbiology, Immunology and Infection (2022) recommends a 3‑g oral dose every 48–72 h for three total doses in patients who have failed prior therapy, are infected with multidrug‑resistant (MDR) pathogens (including ESBL‑producing E. coli, carbapenem‑resistant Enterobacterales, or vancomycin‑resistant enterococci), or cannot tolerate first‑line agents. Weak recommendation, very low quality of evidence (2D). 19

Infection Subtype	Clinical Cure Rate (n/N)	Microbiological Eradication
Acute uncomplicated cystitis	94.71 % (179/189)	97.65 %
Recurrent lower UTI	77.22 % (61/79)	94.44 %
Complicated lower UTI	62.69 % (42/67)	83.87 %

Overall drug‑related adverse events occurred in *5.6 %** of patients, most commonly diarrhea; no serious adverse events were reported. 19

For uncomplicated VRE UTI, a single 3‑g oral dose of fosfomycin is advised.
For complicated VRE UTI, the regimen is three 3‑g oral doses given every 48–72 h.
These recommendations carry a weak recommendation, very low quality of evidence (2D). 19